Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease

N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Autoantibodies / blood
  • Dermatomyositis / complications*
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / therapeutic use
  • Historically Controlled Study
  • Humans
  • Interferon-Induced Helicase, IFIH1 / immunology
  • Janus Kinase Inhibitors / therapeutic use*
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / etiology
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Piperidines / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Pyrroles / therapeutic use*

Substances

  • Autoantibodies
  • Glucocorticoids
  • Janus Kinase Inhibitors
  • Piperidines
  • Pyrimidines
  • Pyrroles
  • tofacitinib
  • IFIH1 protein, human
  • Interferon-Induced Helicase, IFIH1
  • Methylprednisolone

Supplementary concepts

  • Amyopathic dermatomyositis